Abstract
This study investigated the efficacy of preventive role of NAD-containing cardiotrophic drug Adenocine® in chronic isopreterenol (ISO)-induced cardiac hypertrophy (CH) on tissue antioxidant status. On the 14 days of ISO-induced CH (10 mg/kg daily ) all male chinchilla rabbits were randomly assigned into 3 groups: control - infusion of 0,9% NaCl; main I - receive 10 mg/kg nebivolol per os in combination with lisinopril (10 mg/kg) infusion (traditional treatment (TT)); and main II - receive intravenously 15 mg/kg of Adenocin dissolved in water for injection during 7 days. The increases of heart weight by 18,6% and heart-to-body weight ratio by 35,5% observed in CH were significantly suppressed in Adenocin-treated group by 15,8 and 31,5% and only by 6,4 and 9,7% respectively after TT. ISO-induced CH is associated with loss of NAD from 6,4±0,3 to 5,1±0,4mMol/mg. TT didn’t cause the restoration NAD/NADH and NAD content in LV myocardium and decrease level of BNP. Adenocin treatment restored the normal level of NAD+/NADH, increased the activity of CuZn–SOD, Mn–SOD,superoxide anion production, catalase activities and decreased the content of MDA while the TT did not. Conclusion The results described the benficial cardioprotective effect of Adenocin on the the activities of both enzymatic and non-enzymatic antioxidants LV myocardium of ISO-induced CHF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
